There are 2867 resources available
553P - Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: Descriptive analysis of the French cohort temporary authorization of use (ATU)
Presenter: Manuel Rodrigues
Session: Poster session 09
554P - Does the type of hysterectomy affect the survival of patients with clinical IA endometrial cancer: A multicenter and retrospective study
Presenter: Chenmian Liu
Session: Poster session 09
556P - Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study
Presenter: Yue Zhang
Session: Poster session 09
557P - Tumour mutation burden is a dispensable test in endometrial carcinoma patients whose molecular classification is known
Presenter: Huiping Jiang
Session: Poster session 09
558P - Molecular subtyping endometrial carcinoma in Chinese population applying an NGS-based classifier and its association with prognosis
Presenter: Qing Zhang
Session: Poster session 09
559P - Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial
Presenter: Claire Friedman
Session: Poster session 09
560P - Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): A prospective, single-arm, phase II trial
Presenter: Jing Chen
Session: Poster session 09
561P - When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study
Presenter: Monika Hampl
Session: Poster session 09
562P - Camrelizumab plus concurrent chemoradiotherapy for locally advanced cervical cancer: Preliminary results of a single-arm, open-label, phase II trial
Presenter: Yan Xiao
Session: Poster session 09